UPCC 31216: Phase I/II Trial of Regorafenib Hydroxychloroquine and Entinostat in Metastatic Colorectal Cancer
Brief description of study
The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with regorafenib and entinostat.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Colorectal Cancer
-
Age: - 99 Years
-
Gender: All
Updated on
30 Jan 2020.
Study ID: 827226